Limits...
Comparison of long-term oncologic outcomes of stage III colorectal cancer following laparoscopic versus open surgery.

Baek JH, Lee GJ, Lee WS - Ann Surg Treat Res (2014)

Bottom Line: The primary endpoints were disease-free survival and overall survival.A total of 230 patients were entered into the study (114 patients had colon cancer-33 underwent LS and 81 underwent OS; 116 patients had rectal cancer-44 underwent LS and 72 underwent OS).The long-term analyses for oncologic aspects of our study may confirm the safety of LS compared to OS in stage III colorectal cancer patients.

View Article: PubMed Central - PubMed

Affiliation: Division of Colon and Rectal Surgery, Department of Surgery, Gachon University Gil Medical Center, Gachon University School of Medicine,Incheon, Korea.

ABSTRACT

Purpose: The oncologic outcomes after performing laparoscopic surgery (LS) compared to open surgery (OS) are still under debate and a concern when treating patients with colon cancer. The aim of this study was to compare the long-term oncologic outcomes of LS and OS as treatment for stage III colorectal cancer patients.

Methods: From January 2001 to December 2007, 230 patients with stage III colorectal cancer who had undergone LS or OS in this single center were assessed. Data were analyzed according to intention-to-treat. The primary endpoints were disease-free survival and overall survival.

Results: A total of 230 patients were entered into the study (114 patients had colon cancer-33 underwent LS and 81 underwent OS; 116 patients had rectal cancer-44 underwent LS and 72 underwent OS). The median follow-up periods for the colon and rectal cancer groups were 54 and 53 months, respectively. The overall conversion rate was 12.1% (n = 4) for colon cancer, and 4.5% (n = 2) for rectal cancer. Disease-free 5-year survival of colon cancer was 84.3% and 90% in LS group (LG) and OS group (OG), respectively, and that of rectal cancer was 83% and 74.6%, respectively (P > 0.05). Overall 5-year survival for colon cancer was 72.2% and 71.3% for LG and OG, respectively, and that for rectal cancer was 67.6% and 59.2%, respectively (P > 0.05).

Conclusion: The long-term analyses for oncologic aspects of our study may confirm the safety of LS compared to OS in stage III colorectal cancer patients.

No MeSH data available.


Related in: MedlinePlus

Overall survival (OS) of stage III colon cancer patients. LG, laparoscopic surgery group; OG, open surgery group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4279992&req=5

Figure 3: Overall survival (OS) of stage III colon cancer patients. LG, laparoscopic surgery group; OG, open surgery group.

Mentions: The median follow-up for our study was 54 months for colon cancer and 53 months for rectal cancer. There were no port site or specimen-extraction site recurrence after LS or OS. Overall recurrence rate for colon cancer was 15.2% (n = 5) and 11.1% (n = 9) in the LG and OG, respectively. The recurrence rate for rectal cancer was 13.6% (n = 6) in the LG and 23.6% (n = 17) in the OG (Table 3). There was no difference in local recurrence rate for right colon cancer between two groups, and same as for left colon cancer (P > 0.05). Disease-free survival rate at five years was 84.3% and 90.0% in the LG and OG, respectively, for colon cancer (Fig. 1), and 83.0% and 74.6% for rectal cancer (P > 0.05) (Fig. 2). Overall five-year survival rate was 72.2% and 71.3% in the LG and OG for colon cancer (Fig. 3), and 67.6% and 59.2% for rectal cancer, respectively (P > 0.05) (Fig. 4).


Comparison of long-term oncologic outcomes of stage III colorectal cancer following laparoscopic versus open surgery.

Baek JH, Lee GJ, Lee WS - Ann Surg Treat Res (2014)

Overall survival (OS) of stage III colon cancer patients. LG, laparoscopic surgery group; OG, open surgery group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4279992&req=5

Figure 3: Overall survival (OS) of stage III colon cancer patients. LG, laparoscopic surgery group; OG, open surgery group.
Mentions: The median follow-up for our study was 54 months for colon cancer and 53 months for rectal cancer. There were no port site or specimen-extraction site recurrence after LS or OS. Overall recurrence rate for colon cancer was 15.2% (n = 5) and 11.1% (n = 9) in the LG and OG, respectively. The recurrence rate for rectal cancer was 13.6% (n = 6) in the LG and 23.6% (n = 17) in the OG (Table 3). There was no difference in local recurrence rate for right colon cancer between two groups, and same as for left colon cancer (P > 0.05). Disease-free survival rate at five years was 84.3% and 90.0% in the LG and OG, respectively, for colon cancer (Fig. 1), and 83.0% and 74.6% for rectal cancer (P > 0.05) (Fig. 2). Overall five-year survival rate was 72.2% and 71.3% in the LG and OG for colon cancer (Fig. 3), and 67.6% and 59.2% for rectal cancer, respectively (P > 0.05) (Fig. 4).

Bottom Line: The primary endpoints were disease-free survival and overall survival.A total of 230 patients were entered into the study (114 patients had colon cancer-33 underwent LS and 81 underwent OS; 116 patients had rectal cancer-44 underwent LS and 72 underwent OS).The long-term analyses for oncologic aspects of our study may confirm the safety of LS compared to OS in stage III colorectal cancer patients.

View Article: PubMed Central - PubMed

Affiliation: Division of Colon and Rectal Surgery, Department of Surgery, Gachon University Gil Medical Center, Gachon University School of Medicine,Incheon, Korea.

ABSTRACT

Purpose: The oncologic outcomes after performing laparoscopic surgery (LS) compared to open surgery (OS) are still under debate and a concern when treating patients with colon cancer. The aim of this study was to compare the long-term oncologic outcomes of LS and OS as treatment for stage III colorectal cancer patients.

Methods: From January 2001 to December 2007, 230 patients with stage III colorectal cancer who had undergone LS or OS in this single center were assessed. Data were analyzed according to intention-to-treat. The primary endpoints were disease-free survival and overall survival.

Results: A total of 230 patients were entered into the study (114 patients had colon cancer-33 underwent LS and 81 underwent OS; 116 patients had rectal cancer-44 underwent LS and 72 underwent OS). The median follow-up periods for the colon and rectal cancer groups were 54 and 53 months, respectively. The overall conversion rate was 12.1% (n = 4) for colon cancer, and 4.5% (n = 2) for rectal cancer. Disease-free 5-year survival of colon cancer was 84.3% and 90% in LS group (LG) and OS group (OG), respectively, and that of rectal cancer was 83% and 74.6%, respectively (P > 0.05). Overall 5-year survival for colon cancer was 72.2% and 71.3% for LG and OG, respectively, and that for rectal cancer was 67.6% and 59.2%, respectively (P > 0.05).

Conclusion: The long-term analyses for oncologic aspects of our study may confirm the safety of LS compared to OS in stage III colorectal cancer patients.

No MeSH data available.


Related in: MedlinePlus